Disorders A - Z:   A    B   C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z

Skip secondary menu

Funding News - Preclinical Therapeutics Development for NeuroAIDS Sought

Archive folder iconHistorical Data

  • The information on this page is for historical and research purposes only.
  • For the most current NINDS funding announcements, please see the NINDS list of Active Funding Initiatives or Follow Us on Twitter for the latest funding news.

The National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of Mental Health (NIMH), and the National Institute of Drug Abuse (NIDA) invite applications for preclinical therapeutics development for neuroAIDS. This announcement is supported by 2 grant funding mechanisms: R03 and R21.*

Since the availability of the first antiretroviral therapy in 1987 and sequential discoveries of other antiretroviral agents, there has been a dramatic decrease in mortality and morbidity among the HIV/AIDS population. However, despite these important advances, the prevalence of HIV-associated mental and neurological disorders is increasing, in part, because of the prolonged lifespan of infected patients.

Research areas of interest include, but are not limited to: the development of in vitro assays or cell systems that detect HIV replication or activation in appropriate central nervous system (CNS) or CNS-related/derived cell types; studies to devise new approaches for increasing the permeability of antiretroviral agents or other related therapeutic compounds through the blood-brain barrier (BBB); studies to address the effects of drugs of abuse on the BBB; the development of animal models of HIV neuropathogenesis ultimately for use in screening therapeutic compounds or treatment strategies; validating existing animal models of HIV/SIV pathogenesis for use in screening the therapeutic potential of compounds or treatment strategies; the development of new models or validation of existing models of HIV neuropathogenesis in the context of drug abuse or withdrawal for use in screening the therapeutic potential of compounds or treatment strategies appropriate for the drug-addicted population; and the development of novel models of toxicity that are sensitive to CNS developmental stages and vulnerabilities.

For more information, potential applicants should contact Dr. Michael Nunn, Program Director, Neural Environment Cluster, NINDS, Neuroscience Center, 6001 Executive Boulevard, Room 2115, Bethesda, MD 20892; telephone: 301-496-1431; fax: 301-402-2060; e-mail: mn52e@nih.gov.

*For a more detailed description of this announcement, please visit the NIH web site at: http://grants.nih.gov/grants/guide/pa-files/PA-06-140.html (R03), or http://grants.nih.gov/grants/guide/pa-files/PA-06-139.html (R21).